Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 17/20 | 0.82 |
| ▸ | CDK2 | P24941 | 5/20 | 0.82 |
| ▸ | CDK1 | P06493 | 4/20 | 0.82 |
| ▸ | GSK3A | P49840 | 6/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.54 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.54 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.54 |
| ▸ | FLT4 | P35916 | 2/20 | 0.54 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.54 |
| ▸ | CLK2 | P49760 | 2/20 | 0.54 |
| ▸ | TAOK1 | Q7L7X3 | 2/20 | 0.54 |
| ▸ | SLK | Q9H2G2 | 2/20 | 0.54 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.54 |
| ▸ | PLK4 | O00444 | 1/20 | 0.54 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.54 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.54 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.54 |
| ▸ | PIM1 | P11309 | 1/20 | 0.54 |
| ▸ | MARK3 | P27448 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4381668 | 0.86 | GSK3B (0.60) | GSK3BCDK2CDK1GSK3APRKAA1 | |
| SCHEMBL2332408 | 0.84 | GSK3B (0.60) | GSK3BCDK2CDK1GSK3ACYP1A2 | |
| SCHEMBL4392816 | 0.81 | GSK3B (0.61) | GSK3BCDK2CDK1GSK3ACDK5 | |
| SCHEMBL1461843 | 0.81 | GSK3B (1.00) | GSK3BCDK2CDK1GSK3ACYP1A2 | |
| SCHEMBL1461503 | 0.80 | GSK3B (0.59) | GSK3BCDK2CDK1GSK3ACYP1A2 | |
| SCHEMBL2333341 | 0.78 | GSK3B (0.53) | GSK3BCDK2CDK1GSK3AMAPK1 | |
| SCHEMBL1461347 | 0.77 | GSK3B (1.00) | GSK3BCDK2CDK1GSK3ACYP1A2 | |
| SCHEMBL1377235 | 0.77 | GSK3B (0.52) | GSK3BCDK2CDK1GSK3A | |
| SCHEMBL1377394 | 0.77 | GSK3B (0.58) | GSK3BCDK2CDK1GSK3ACYP1A2 | |
| SCHEMBL4392791 | 0.77 | GSK3B (0.76) | GSK3BCDK2CDK1GSK3ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1487804-B1 | AMINOINDAZOLE DERIVATIVES AS PROTEIN-KINASE INHIBITORS | AVENTIS PHARMA SA (FR) | 2014-02-26 | — | — | EP | claimed |
| JP-4648630-B2 | — | — | 2011-03-09 | — | — | JP | claimed |
| JP-2005530711-A | — | — | 2005-10-13 | — | — | JP | claimed |
| US-6949579-B2 | Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof | AVENTIS PHARMA S.A. (FR) | 2005-09-27 | — | — | US | claimed |
| EP-1487804-A2 | AMINOINDAZOLE DERIVATIVES AS PROTEIN-KINASE INHIBITORS | Aventis Pharma S.A. (FR) | 2004-12-22 | — | — | EP | claimed |
| US-20040014802-A1 | Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof | AVENTIS PHARMA S.A. (FR) | 2004-01-22 | — | — | US | claimed |
| WO-2003078403-A2 | DERIVES D’AMINOINDAZOLES COMME INHIBITEURS DE PROTEINE-KINASE | AVENTIS PHARMA S.A. (FR) | 2003-09-25 | — | — | WO | claimed |
| EP-1487804-B1 | AMINOINDAZOLE DERIVATIVES AS PROTEIN-KINASE INHIBITORS | AVENTIS PHARMA SA (FR) | 2014-02-26 | — | — | EP | disclosed |
| US-6949579-B2 | Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof | AVENTIS PHARMA S.A. (FR) | 2005-09-27 | — | — | US | disclosed |
| EP-1487804-A2 | AMINOINDAZOLE DERIVATIVES AS PROTEIN-KINASE INHIBITORS | Aventis Pharma S.A. (FR) | 2004-12-22 | — | — | EP | disclosed |
| US-20040014802-A1 | Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof | AVENTIS PHARMA S.A. (FR) | 2004-01-22 | — | — | US | disclosed |
| WO-2003078403-A2 | DERIVES D’AMINOINDAZOLES COMME INHIBITEURS DE PROTEINE-KINASE | AVENTIS PHARMA S.A. (FR) | 2003-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014802-A1 | Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof | CYP2C8, NR0B2, NR2C2 | GSK3B 2342/4885CDK2 1677/4885CDK1 2364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.